|Source:||The roots of Eleutherococcus senticosus|
|Biological Activity or Inhibitors:||1. Eleutheroside E has anti-inflammatory effects by inhibiting NF-κB activities.
2. Eleutheroside E significantly decreases the inflammatory cell infiltration, pannus formation, cartilage damage, bone erosion of CIA mice, the generation of TNF-α and IL-6, the metabolism of drugs metabolized via CYP2C9 and CYP2E1.
3. Eleutheroside E may treat rheumatoid arthritis or increase the toxicity of the drugs.
|Solvent:||Pyridine, Methanol, Ethanol, etc.|
|Storage:||Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: firstname.lastname@example.org
|After receiving:||The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.|
|1 mg||5 mg||10 mg||20 mg||25 mg|
|1 mM||1.3464 mL||6.7319 mL||13.4638 mL||26.9277 mL||33.6596 mL|
|5 mM||0.2693 mL||1.3464 mL||2.6928 mL||5.3855 mL||6.7319 mL|
|10 mM||0.1346 mL||0.6732 mL||1.3464 mL||2.6928 mL||3.366 mL|
|50 mM||0.0269 mL||0.1346 mL||0.2693 mL||0.5386 mL||0.6732 mL|
|100 mM||0.0135 mL||0.0673 mL||0.1346 mL||0.2693 mL||0.3366 mL|
Arch Pharm Res. 2015 Mar 25.
|Utilization of circular dichroism experiment to distinguish acanthoside D and eleutheroside E.[Pubmed: 25802110 ]|
|Two lignan glycosides, acanthoside D (1) (=liriodendrin, (+)-syringaresinol di-O-β-D-glucopyranoside) and Eleutheroside E (2) have been confused each other for so long time, and hard to be distinguished each other. Now, this two compounds need to be defined properly so that all the commercial mistakes and confusions should not be made. They have identical planar structures except for the configurations at C-7 and C-8 in each structure according to the chemistry database, SciFinder®. The systematic name of acanthoside D is [(1S,3aR,4S,6aR)-tetrahydro-1H,3H-furo[3,4-c]furan-1,4-diyl]bis(2,6-dimethoxy-4,1-phenylene) bis-β-D-glucopyranoside (1), and the name of Eleutheroside E is [(1R,3aR,4S,6aS)-tetrahydro-1H,3H-furo[3,4-c]furan-1,4-diyl]bis(2,6-dimethoxy-4,1-phenylene) bis-β-D-glucopyranoside (2). The differences at two chiral centers do not make any differences in the NMR spectra. Thus, the circular dichroism were utilized to dissolve this difficult problem. Acanthoside D (1) showed a positive Cotton effect at 200 nm, whereas Eleutheroside E (2) exhibited a negative cotton effect at 200 nm. The absolute structure of acanthoside D was also confirmed by X-ray crystallography.|
Zhongguo Zhong Yao Za Zhi. 2014 May;39(10):1921-7.
|[Comparative pharmacokinetics of syringin, eleutheroside E and isofraxidin in rat plasma after intravenous administration of each monomer and Ciwujia injection].[Pubmed: 25282907 ]|
|To compare the pharmacokinetics of syringin, Eleutheroside E and isofraxidin after intravenous administration of each monomer and Ciwujia injection. Twenty-four Sprague-Dawley rats were randomly divided into four groups and intravenously administrated with syringin, Eleutheroside E, isofraxidin, and Ciwujia injection, respectively. The concentrations of the three components in rat plasma were determined by LC-MS/MS. DAS 2.0 software was applied to calculate the pharmacokinetic parameters while the SPSS 17.0 software was used for statistical analysis. Significant difference (P < 0.05) was found between each monomer and the injection on the main pharmacokinetic parameters such as AUC, CL and t1,/2. Compared with the injection, the group treated with the syringin has obvious decrease in AUC, and increase in CL while the group treated with Eleutheroside E has obvious increase in AUC, and decrease in CL The t1/2 of isofraxidin was prolonged in Ciwujia injection. Pharmacokinetic characters of the ingredients in the injection varied greatly from the monomer. Other constituents in the injection may have an impact on the pharmacokinetic profiles of these three components.|
Inflammation. 2014 Oct;37(5):1533-43.
|Eleutheroside E ameliorates arthritis severity in collagen-induced arthritis mice model by suppressing inflammatory cytokine release.[Pubmed: 24917466]|
|Rheumatoid arthritis is the most common arthritis and is mainly characterized by symmetric polyarticular joint disorders. Eleutheroside E (EE), a principal active constituent of Acanthopanax senticosus, is reported to have anti-inflammatory effect by inhibiting NF-κB activities. However, the effects of Eleutheroside E on rheumatoid arthritis (RA) severity are largely unknown. The purpose of this study was to indicate whether Eleutheroside E could ameliorate arthritis and reduce inflammatory cytokine release in collagen-induced arthritis (CIA) mice. The results showed that Eleutheroside E attenuated the severity of arthritis by reducing the mean arthritis score and arthritis incidence. Eleutheroside E also significantly decreased the inflammatory cell infiltration, pannus formation, cartilage damage, and bone erosion of CIA mice. Furthermore, Eleutheroside E caused a marked decrease of the production of TNF-α and IL-6 in vivo and in vitro. These observations identify a novel function of Eleutheroside E that results in inhibition of cytokine release, highlighting Eleutheroside E was a potential therapeutic agent for RA.|
BMC Complement Altern Med. 2014 Jan 2;14:1.
|Effects of eleutheroside B and eleutheroside E on activity of cytochrome P450 in rat liver microsomes.[Pubmed: 24383621]|
|This study was to investigate the effects of EB and Eleutheroside E on CYP2C9, CYP2D6, CYP2E1 and CYP3A4 in rat liver microsomes in vitro. METHOD: Probe drugs of tolbutamide (TB), dextromethorphan (DM), chlorzoxazone (CLZ) and testosterone (TS) as well as eleutherosides of different concentrations were added to incubation systems of rat liver microsomes in vitro. After incubation, validated HPLC methods were used to quantify relevant metabolites. RESULTS: The results suggested that EB and Eleutheroside E exhibited weak inhibition against the activity of CYP2C9 and CYP2E1, but no effects on CYP2D6 and CYP3A4 activity. The IC50 values for EB and Eleutheroside E were calculated to be 193.20 μM and 188.36 μM for CYP2E1, 595.66 μM and 261.82 μM for CYP2C9, respectively. Kinetic analysis showed that inhibitions of CYP2E1 by EB and Eleutheroside E were best fit to mixed-type with Ki value of 183.95 μM and 171.63 μM, respectively. CONCLUSIONS: These results indicate that EB and Eleutheroside E may inhibit the metabolism of drugs metabolized via CYP2C9 and CYP2E1, and have the potential to increase the toxicity of the drugs.|